Cerebral edema following photodynamic therapy using endogenous and exogenous photosensitizers in normal brain

Lasers in Surgery and Medicine

Volumn 43, Issue 9, 2011, Pages 892-900

  Mathews, Marlon S ^a,b   Chighvinadze, David ^c   Gach, H Michael ^c,d   Uzal, Francisco A ^e   Madsen, Steen J ^c   Hirschberg, Henry ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEVADA   (United States)

^d NEVADA CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ALA; AlPcS2a; aluminum phthalocyanine disulfonate; amino levulenic acid; cerebral edema; endogenous photosensitizer; exogenous photosensitizer; PDT; photodynamic therapy; vasogenic edema

Indexed keywords

AMINOLEVULINIC ACID; PHOTOFRIN; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN TISSUE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HISTOPATHOLOGY; ILLUMINATION; IMAGE ANALYSIS; INTERSTITIUM; LASER; LIGHT RELATED PHENOMENA; LOW LEVEL LASER THERAPY; MALE; MORTALITY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; RAT; SKULL;

ANIMALS; BRAIN EDEMA; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RATS; RATS, INBRED F344;

EID: 80055003121     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21135     Document Type: Article

References (41)

1. CBTRUS Statistical Report: Primary Brain Tumors in the United States 2004-2007, the Central Brain Tumor Registry of the United States. Accessed June 2011.
2. Salcman M,. Epidemiology and factors affecting survival. In:, Apuzzo MLJ, editor. Malignant cerebral glioma. IL: American Association of Neurological Surgeons; 1990. pp 95-109.
3. Hirschberg H, Samset E, Hole PK, Lote K,. Impact of intraoperative MRI on the results of surgery for high grade gliomas. J Minim Invasive Neurosurg 2006; 8 (2): 77-84.
4. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ,. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomized controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
5. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 2008; 62 (3): 564-576.
6. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG,. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405-1409.
7. Muller PJ, Wilson BC, Lilge LD, Yang V, Hetzel FW, Chen Q, Selker R, Abrams J,. Photofrin photodynamic therapy for malignant brain tumors. Proc SPIE 2001; 4248: 34-41.
8. Eljamel MS, Goodman C, Moseley H,. ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: A single centre phase III randomised controlled trial. Lasers Med Sci 2008; 23: 361-367.
9. Frisen S, Hjortland GO, Hirschberg H, Engebraaten O, Madsen SJ, Nesland JM, Peng Q,. 5-Aminolevulinic acid based photodynamic detection and therapy of brain tumors. Int J Oncol 2002; 21 (3): 577-582.
10. Maman N, Dhami S, Phillips D, Brault D,. Kinetic and equilibrium studies of incorporation of di-sulfonated aluminum phthalocyanine into unilamellar vesicles. Biochim Biophys Acta 1999; 1420: 168-178.
11. Høgset A, Prasmickaite L, Selbo P, Hellum M, Engesæter B, Bonsted A, Berg K,. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004; 56: 95-115.
12. Berg K, Bommer J, Moan J,. Evaluation of sulfonated aluminum phthalocyanines for use in photochemotherapy. Cellular uptake studies. Cancer Lett 1989; 44: 7-15.
13. Paquette B, Ali H, Langlois R, Van Lier J,. Biological activities of phthalocyanines-VIII. Cellular distribution in V-79 Chinese Hamster cells and phototoxicity of selectively sulfonated aluminum phthalocyanines. Photochem Photobiol 1988; 47: 215-220.
14. Fingar VH,. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996; 14: 323-328.
15. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW,. Photodynamic therapy: A means to enhanced drug delivery to tumors. Cancer Res 2003; 63: 8126-8131.
16. Debefve E, Pegaz B, Ballini JP, Konan YN, Van den Bergh H,. Combination therapy using aspirin enhanced photodynamic selective drug delivery. Vasc Pharmacol 2007; 46: 171-180.
17. Debefve E, Pegaz B, van den Bergh H, Wagnieres G, Lange N, Ballini JP,. Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model. Angiogenesis 2008; 11: 235-243.
18. Stummer W, Goetz C, Hassan A, Heimann DVM, Kempski O,. Kinetics of Photofrin II in perifocal brain edema. Neurosurgery 1993; 33: 1075-1082.
19. Goetz C, Hasan A, Stummer W, Heimann A, Kempski O,. Experimental research photodynamic effects in perifocal, oedematous brain tissue. Acta Neurochir (Wien) 2002; 144 (2): 173-179.
20. Ito S, Rachinger W, Stepp H, Reulen HJ, Stummer W,. Oedema formation in experimental photo-irradiation therapy of brain tumours using 5-ALA. Acta Neurochir (Wien) 2005; 147 (1): 57-65.
21. Hirschberg H, Uzal FA, Chighvinadze D, Zhang MJ, Peng Q, Madsen SJ,. Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy. Lasers Surg Med 2008; 40 (8): 535-542.
22. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM,. 5-Aminolevulinic acid-based photodynamic therapy: Principles and experimental research. Photochem Photobiol 1997; 65: 235-251.
23. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky K-E, Nesland JM,. 5-aminolevulinic acid-based photodynamic therapy: Clinical research and future challenges. Cancer 1997; 79: 2282-2308.
24. Madsen SJ, Sun CH, Tromberg BJ, Hirschberg H,. Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid. Photochem Photobiol 2000; 72: 128-134.
25. Sporn LA, Foster TH,. Photofrin and light induces microtubule depolymerization in cultured human endothelial cells. Cancer Res 1992; 52: 3443-3448.
26. Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H, Stummer W, Baumgartner R,. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 2007; 39 (5): 386-393.
27. Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM,. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res 2001; 61 (15): 5824-5832.
28. Angell-Petersen E, Hirschberg H, Madsen SJ,. Determination of fluence rate and temperature distributions in the rat brain; implications for photodynamic therapy. J Biomed Opt 2007; 12 (1): 014003.
29. Ballabh P, Braun A, Nedergaard M,. The blood-brain barrier: An overview: Structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13.
30. Abbott N,. Physiology of the blood-brain barrier and its consequences for drug transport to the brain. Int Congr Ser 2005; 1277: 3-18.
31. Abbott N, Romero I,. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996; 2: 106-113.
32. Gobiet W, Grote W, Bock WJ,. The relation between intracrainal pressure, mean arterial pressure and cerebral blood flow in patients with severe head injury. Acta Neurochir (Wien) 1975; 32 (1-2): 13-24.
33. Tweed WA, Overgaard J,. Cerebral blood flow in patients with intracranial pressure elevation due to traumatic brain edema. Can J Neurol Sci 1976; 3 (1): 35-37.
34. Graham DI, Lawrence AE, Adams JH, Doyle D, McLellan DR,. Brain damage in non-missile head injury secondary to high intracranial pressure. Neuropathol Appl Neurobiol 1987; 13 (3): 209-217.
35. Klatzo I,. Pathophysiological aspects of brain edema. Acta Neuropathol 1987; 72 (3): 236-239.
36. Kuroiwa T, Ueki M, Chen Q, Suemasu H, Taniguchi I, Okeda R,. Biomechanical characteristics of brain edema: The difference between vasogenic-type and cytotoxic-type edema. Acta Neurochir Suppl (Wien) 1994; 60: 158-161.
37. Galicich JH, French LA, Melby JC,. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet 1961; 81: 46-53.
38. Rasmussen T, Gulati DR,. Cortisone in the treatment of postoperative cerebral edema. J Neurosurg 1962; 19: 535-544.
39. GÃrde A,. Experiences with dexamethasone treatment of intracranial pressure caused by brain tumours. Acta Neurol Scand Suppl 1965; 13 (Pt 2): 439-443.
40. Johnson JA, Assam S,. Use of betamethasone in reduction of cerebral edema. Mil Med 1966; 131 (1): 44-47.
41. Roth P, Wick W, Weller M,. Steroids in neurooncology: Actions, indications, side-effects. Curr Opin Neurol 2010; 23 (6): 597-602.